热门资讯> 正文

BRIEF-Travere Therapeutics Provides Corporate Update And 2025 Outlook

2025-01-13 21:39

Jan 13 (Reuters) - Travere Therapeutics Inc TVTX.O:

TRAVERE THERAPEUTICS PROVIDES CORPORATE UPDATE AND 2025 OUTLOOK
SNDA FOR MODIFICATION OF LIVER MONITORING FOR FILSPARI IN IGAN ACCEPTED FOR FDA REVIEW ; PDUFA TARGET ACTION DATE OF AUG 28
ON TRACK TO PROVIDE REGULATORY UPDATE ON SPARSENTAN IN FSGS BY ITS Q4 2024 EARNINGS CALL
EXPECTS FISCAL YEAR 2024 NET PRODUCT SALES TO BE APPROXIMATELY $227 MILLION

Source text: ID:nGNX4n2d4x

Further company coverage: TVTX.O

((Reuters.Briefs@thomsonreuters.com;))

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。